ALBANY, New York, Oct. 3,
2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a premier
contract services provider to the life sciences industry, will be
showcasing its comprehensive portfolio of active pharmaceutical
ingredients (APIs) and capabilities at CPhI Worldwide, one of the
pharmaceutical industry's highest profile events, being held this
week in Barcelona. AMRI's July
2016 acquisition of Euticals positions AMRI as one of the
largest independent developers and suppliers of API to the
pharmaceutical industry and provides the company with an
established presence in key European markets.
AMRI provides a broad range of complex Active Pharmaceutical
Ingredients (API) to the Life Sciences industry, including sterile
and high potency APIs, steroids, generics, monobactams, boronic
acids and controlled substances. To access AMRI's full catalog of
APIs, click here.
"As AMRI celebrates its 25th anniversary, CPhI presents the
perfect opportunity to reveal AMRI and Euticals as one combined
company that can offer a greatly expanded portfolio of
market-leading APIs and world-class capabilities in niche and
high-barrier-to-entry technologies," said Margalit Fine, executive vice president of API
at AMRI. "In addition to an extensive API portfolio, we can now
offer our customers U.S. and European-based chemical development
expertise for early stage compounds, custom synthesis and contract
manufacturing expertise, as well as extensive technology expertise
in specialty areas such as hydrogenation, fermentation,
photocatalytic chemistry, bio transformation, industrial
chromatography, flow chemistry and spray drying."
Attracting about 2,490 exhibitors and in excess of 36,000
participants from more than 150 countries, CPhI Worldwide is one of
the largest events in the pharma industry. This year, CPhI will
take place in Barcelona and run
between October 4th and
6th. Visit AMRI at booth numbers 4F46 or 3Q10.
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract
research and manufacturing organization that has been working with
the Life Sciences industry to improve patient outcomes and the
quality of life for more than two decades. With locations
in North America, Europe and Asia, our key
business segments include Discovery and Development Services (DDS),
Active Pharmaceutical Ingredients (API), Drug Product Manufacturing
(DPM), and Fine Chemicals. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).